VivoSeq
Oncology

Tenosynovial Giant Cell Tumor

2

Pipeline Programs↗

2

Active Trials↗

3

Companies Involved↗

Tenosynovial Giant Cell Tumor is an early-stage landscape with 2 programs across 3 companies. The most active players are Abbisko Therapeutics Co, Ltd, Daiichi Sankyo, Merck & Co.. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Abbisko Therapeutics Co, Ltd

1 program

Phase 2Daiichi Sankyo logo

Daiichi Sankyo

1 program

Phase 3Merck & Co. logo

Merck & Co.

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 21

Pimicotinib

Abbisko Therapeutics Co, Ltd

Phase 31

Pexidartinib

Daiichi Sankyo

Approved
No programs

Analysis

Trial Status

3

clinical trials

Recruiting1 · 33%
Active, not recruiting1 · 33%
Completed1 · 33%

Clinical Trials

Trial Activity

Phase 2, Single-arm Study to Investigate the Tolerability, Pharmacokinetics, Efficacy, and Safety of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor
Recruiting·Merck & Co. logoMerck & Co.·Phase 2·NCT07499362·20 enrolled
Multicenter, Single Arm Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With Tenosynovial Giant Cell Tumor
Active, not recruiting·Daiichi Sankyo logoDaiichi Sankyo·Phase 3·NCT04488822·40 enrolled
A Phase 2, Multicenter, Two-Part, Open-Label Study of Pexidartinib in Adult Subjects With Tenosynovial Giant Cell Tumor in Japan
Completed·Daiichi Sankyo logoDaiichi Sankyo·Phase 2·NCT04703322·9 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)